FDA label 83236a0c-87f1-4706-957c-ceb65a9ce4b0
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 33d8ecac-2bb9-44b5-8016-3bb37db38eb5
- SPL ID
- 83236a0c-87f1-4706-957c-ceb65a9ce4b0
- Version
- 12
- Effective date
- 2020-04-02
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:32
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 83236a0c-87f1-4706-957c-ceb65a9ce4b0 | id | |
| spl set id | 33d8ecac-2bb9-44b5-8016-3bb37db38eb5 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, discontinue treatment with ADYNOVATE and administer appropriate treatment. ( 5.1 ) Development of factor VIII neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration. ( 5.2 , 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions are possible with ADYNOVATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with other recombinant antihemophilic factor VIII products, including the parent molecule, ADVATE. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of ADYNOVATE. Monitor patients regularly for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests. Perform an assay that measures factor VIII inhibitor concentration if the plasma factor VIII level fails to increase as expected, or if bleeding is not controlled with expected dose. 5.3 Monitoring Laboratory Tests Monitor plasma factor VIII activity by performing a validated one-stage clotting assay to confirm the adequate factor VIII levels have been achieved and maintained [see Dosage and Administration (2) ]. Monitor for the development of factor VIII inhibitors. Perform the Bethesda inhibitor assay to determine if factor VIII inhibitor is present. If expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with the expected dose of ADYNOVATE, use Bethesda Units (BU) to determine inhibitor levels.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (≥1% of subjects) reported in the clinical studies were headache and nausea. The most common adverse reactions reported in ≥1% of subjects in the clinical studies were headache and nausea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxalta US Inc.at 1-800-999-1785 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The safety of ADYNOVATE was evaluated in 237 previously treated patients (PTPs) and 6 previously untreated patients (PUPs) with severe hemophilia A (factor VIII less than 1% of normal), who received at least one dose of ADYNOVATE in 3 completed multi-center, prospective, open label clinical studies and 4 ongoing clinical studies. The median duration of participation per subject was 401 (min-max: 3-1034) days and the median number of exposure days to ADYNOVATE per subject was 111 (min-max: 1-322). Table 3 lists the adverse reactions reported during clinical studies. Table 3: Adverse Reactions Reported for ADYNOVATE MedDRA System Organ Class MedDRA Preferred Term Number of Subjects n (%) (N=243) Rate of AEs per 100 Infusions (N=30865) Gastrointestinal Disorders Diarrhea 1 (0.4%) 0.003 Nausea 2 (0.8%) 0.006 Immune System Disorder Hypersensitivity The event of hypersensitivity was a mild transient non-serious rash, occurring in one 2-year old patient who had developed a previous rash while on ADYNOVATE. 1 (0.4%) 0.003 Nervous System Disorders Headache 5 (2.1%) 0.026 Skin and Subcutaneous Tissue Disorders Rash 1 (0.4%) 0.003 Vascular Disorders Flushing 1 (0.4%) 0.003 Two cases of acute pancreatitis, with no precipitating cause identified in one case, were reported in adults during an extension study of the clinical trial which evaluated 137 subjects. Administration of ADYNOVATE continued and both cases resolved. 6.2 Immunogenicity The risk of the development of factor VIII inhibitors with the use of ADYNOVATE was evaluated in 3 completed and 4 ongoing clinical trials. Subjects consisted of adolescent and adult (n= 148 with ≥150 prior EDs) and pediatric PTPs [(<6 years of age with ≥50 prior EDs (n= 32), ≥6 years of age with ≥150 prior EDs (n= 57)], and pediatric PUPs (n=6). In 191 adult and pediatric PTPs who were treated for at least 50 exposure days with ADYNOVATE, the factor VIII inhibitor frequency was 0 (95% CI of 0 to 0.019). One PUP subject from an ongoing study, who received at least one infusion of ADYNOVATE, developed neutralizing antibodies to factor VIII. Immunogenicity also was evaluated by measuring the development of binding IgG and IgM antibodies against factor VIII, PEGylated (PEG)-factor VIII, PEG and Chinese hamster ovary (CHO) protein using validated ELISA assays. The majority of subjects (238/243) with at least one infusion of ADYNOVATE did not develop a persistent binding antibody response to any of these antigens. Twenty-eight subjects in total showed pre-existing antibodies to factor VIII (n=3), PEG-factor VIII (n=25) and/or PEG (n=3) prior to the first exposure to ADYNOVATE. Thirteen subjects who tested negative at screening developed transient antibodies against factor VIII (n= 6), PEG-FVIII (n= 8) at one or two consecutive study visits. Antibodies were transient and not detectable at subsequent visits. Five subjects showed positive results for binding antibodies at study completion or at the time of data cutoff. Binding antibodies that were detected prior to exposure to ADYNOVATE, that transiently developed during the trial or were still detectable at study completion or data cutoff could not be correlated to any impaired treatment efficacy or altered PK parameters. There was no causal relationship between observed adverse events and binding antibodies except in one subject where a causal relationship cannot be ruled out based on available data. No subject had pre-existing or treatment-emergent antibodies to CHO protein. The detection of antibodies that are reactive to factor VIII is highly dependent on many factors, including: the sensitivity and specificity of the assay, sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of the incidence of antibodies to ADYNOVATE with the incidence of antibodies to other products may be misleading.
adverse reactions table
<table width="70%"> <caption>Table 3: Adverse Reactions Reported for ADYNOVATE</caption> <col width="43%" align="left" valign="middle"/> <col width="30%" align="left" valign="middle"/> <col width="12%" align="center" valign="middle"/> <col width="15%" align="center" valign="middle"/> <thead> <tr> <th styleCode="Lrule Rrule" align="center">MedDRA System Organ Class</th> <th styleCode="Rrule" align="center">MedDRA Preferred Term</th> <th styleCode="Rrule">Number of Subjects n (%) (N=243)</th> <th styleCode="Rrule">Rate of AEs per 100 Infusions (N=30865)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" rowspan="2">Gastrointestinal Disorders</td> <td styleCode="Rrule">Diarrhea</td> <td styleCode="Rrule">1 (0.4%)</td> <td styleCode="Rrule">0.003</td> </tr> <tr styleCode="Botrule"> <td styleCode="Rrule">Nausea</td> <td styleCode="Rrule" align="center">2 (0.8%)</td> <td styleCode="Rrule">0.006</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Immune System Disorder</td> <td styleCode="Rrule">Hypersensitivity<footnote>The event of hypersensitivity was a mild transient non-serious rash, occurring in one 2-year old patient who had developed a previous rash while on ADYNOVATE.</footnote> </td> <td styleCode="Rrule">1 (0.4%)</td> <td styleCode="Rrule">0.003</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nervous System Disorders</td> <td styleCode="Rrule">Headache</td> <td styleCode="Rrule">5 (2.1%)</td> <td styleCode="Rrule">0.026</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Skin and Subcutaneous Tissue Disorders</td> <td styleCode="Rrule">Rash</td> <td styleCode="Rrule">1 (0.4%)</td> <td styleCode="Rrule">0.003</td> </tr> <tr> <td styleCode="Lrule Rrule">Vascular Disorders</td> <td styleCode="Rrule">Flushing</td> <td styleCode="Rrule">1 (0.4%)</td> <td styleCode="Rrule">0.003</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.